Innovation at Penn
Browse Penn-owned technologies available for licensing.
Targeted drug delivery using red-blood cells for transport
Platform technology for targeted drug delivery using red blood cells for transport.
Drug delivery can often result in up to 99% of the drug being delivered to off-target organs. This can lead to side-effects and toxicities. Current methods that bind drugs to red-blood cells for transport can require modifying the structure of the red blood cell.
A platform technology for targeted drug delivery to target organs while reducing off target drug effects. This platform technology can be used with a variety of small molecule drugs required for treating organ sites without modifying the structure of the red blood cell.
Liposomes have been engineered to display antibodies that target red-blood cells and specific organ-sites, allowing for dual targeting. The liposomes can be loaded with a variety of small molecule drugs. Binding the liposome loaded with the drug molecule to red blood cells allows for leveraging red blood cells as drug shuttles and carriers.
2x greater drug delivery to the targeted organ as compared to passive red blood cell binding
Control of nanocarrier binding to red blood cell to reduce variability
Utilization with a broad range of nanocarriers
Increased plasma half-life of nanocarriers
Stage of Development:
In vivo proof of concept
Docket # 20-9162
Bookmark this page
Download as PDF
For Information, Contact:
Licensing Officer, PSOM Licensing Group
University of Pennsylvania
Therapeutics & Vaccines
© 2021. All Rights Reserved. Powered by